ASX:RHY

Rhythm Biosciences Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive RHY News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Biosciences and its competitors with MarketBeat's FREE daily newsletter.

About Rhythm Biosciences

Rhythm Biosciences Limited engages in developing and commercializing medical diagnostics technology in Australia and internationally. It is developing ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.

Imagine Owning Rhythm Biosciences (ASX:RHY) And Wondering If The 41% Share Price Slide Is Justified
February 19, 2021 | finance.yahoo.com

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?
February 19, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:RHY
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.rhythmbio.com
Phone: N/A
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $1.11 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: A$0.01 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 1.86
Quick Ratio: 1.81

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Rhythm Biosciences.

0.0 Community Rank

Outperform Votes
Rhythm Biosciences has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Rhythm Biosciences has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Rhythm Biosciences and other stocks. Vote “Outperform” if you believe RHY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RHY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Rhythm Biosciences does not currently pay a dividend.
Dividend Growth
Rhythm Biosciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rhythm Biosciences insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Rhythm Biosciences (ASX:RHY) Frequently Asked Questions

What stocks does MarketBeat like better than Rhythm Biosciences?: Wall Street analysts have given Rhythm Biosciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rhythm Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Rhythm Biosciences' key executives?: Rhythm Biosciences' management team includes the following people:
Mr. Glenn Gilbert, CEO & COO
Dr. Trevor John Lockett Ph.D., Technical Director, Chair of the Clinical Advisory Board & Director
Mr. Adrien Michele Wing C.P.A., B.Bus, B.Acc, CPA, Company Sec. (Age 47, Pay $105.6k)
Ms. Pauline Moffatt, Joint Company Sec.
Who are some of Rhythm Biosciences' key competitors?: Some companies that are related to Rhythm Biosciences include Australian Clinical Labs (ACL), BARD1 Life Sciences (BD1), Biomark Diagnostics (BUX), Charles River Laboratories International (CRL), Cryosite (CTE), dorsaVi (DVL), Epigenomics (EPGNY), Eternity Healthcare (ETAH), Genetic Signatures (GSS), Genetic Technologies (GTG), Imagin Medical (IME), Imagion Biosystems (IBX), Integral Diagnostics (IDX), Lifespot Health (LSH) and Med BioGene (MBGNF).
View all of RHY's competitors.
What is Rhythm Biosciences' stock symbol?: Rhythm Biosciences trades on the ASX under the ticker symbol "RHY."
How much money does Rhythm Biosciences make?: Rhythm Biosciences has a market capitalization of $0.00 and generates $1.11 million in revenue each year.
What is Rhythm Biosciences' official website?: The official website for Rhythm Biosciences is www.rhythmbio.com.

This page was last updated on 10/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.